Jose Juan Delgado, MA | |
Cmr 454 Box 2062, Jose J Delgado, Apo, AE 09250 | |
(314) 467-1710 | |
Not Available |
Full Name | Jose Juan Delgado |
---|---|
Gender | Male |
Speciality | Psychologist - Counseling |
Location | Cmr 454 Box 2062, Apo, Armed Forces Europe |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629172879 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | 012 (Puerto Rico) | Secondary |
103TC1900X | Psychologist - Counseling | 310 (Puerto Rico) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jose Juan Delgado, MA Hindenburg Str. 24a, Ruedenhause, BAVARIA 97355 Ph: () - | Jose Juan Delgado, MA Cmr 454 Box 2062, Jose J Delgado, Apo, AE 09250 Ph: (314) 467-1710 |
News Archive
During a visit to the Indian state of Bihar, Bill Gates, co-founder of the Bill & Melinda Gates Foundation, on Thursday discussed his foundation's work in India and global health priorities, ANI/Sify News reports.
Concentra Occupational Health Research Institute (COHRI), the independent medical education and research arm of Concentra, was recently awarded accreditation status as a provider of continuing medical education (CME) for physicians by the Accreditation Council for Continuing Medical Education (ACCME). The accreditation term is effective through July 31, 2012.
Emerging Healthcare Solutions, Inc. announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion.
ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.
› Verified 4 days ago